237 results match your criteria Blepharospasm Benign Essential


Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.

Int Ophthalmol 2022 Mar 30. Epub 2022 Mar 30.

Department of Ophthalmology, Ankara Bilkent City Hospital, Ankara, Turkey.

Purpose: To investigate the effect of botulinum neurotoxin-A (BTX-A) treatment on dry eye symptoms, tear meniscus, corneal topography and corneal aberrometry in patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS).

Materials And Methods: This prospective study comprised of 6 patients with BEB and 20 patients with HFS. Tear meniscus height (TMH) and depth (TMD), tear break-up time (TBUT), corneal fluorescein staining score (CFSS), Schirmer I test, ocular surface disease index (OSDI) score, corneal topography [corneal power of flat axis (K1), corneal power of steep axis (K2), mean corneal power (Km), astigmatism and thinnest pachymetry] and anterior corneal aberrometry [spherical aberration (SA), vertical coma (vcoma), horizontal coma (hcoma), higher order root mean square (hRMS) and total RMS] were evaluated before BTX-A treatment, 3 weeks after BTX-A treatment and 2 months after BTX-A treatment. Read More

View Article and Full-Text PDF

Application of colored filters in patients post-traumatic brain injury: A review.

NeuroRehabilitation 2022 ;50(3):321-330

Nova Southeastern College of Optometry, Fort Lauderdale, FL, USA.

Background: Tinted lenses have been used to manage visual discomfort and photosensitivity in patients with migraines, benign essential blepharospasm (BEB) and epilepsy.

Objectives: The purpose of this review is to examine the existing clinical research regarding the use of colored filters among patients recovering from traumatic brain injuries.

Methods: A review of English articles from PubMed, Embase from embase. Read More

View Article and Full-Text PDF

Ultra-Long-Term Therapy of Benign Essential Blepharospasm with Botulinumtoxin A-30 Years of Experience in a Tertiary Care Center.

Toxins (Basel) 2022 02 7;14(2). Epub 2022 Feb 7.

Department of Ophthalmology, University Hospital of Bonn, Ernst-Abbe-Street 2, D-53127 Bonn, Germany.

Aim of this study was to investigate the long-term results of botulinum toxin A (BoNT-A) injections for the treatment of benign essential blepharospasm (BEB) and to report our experience with (ultra-)long-term treatment with onabotulinumtoxin-A. We conducted a retrospective cross-sectional analysis at a university hospital. Patients with BEB and BoNT-A treatment were assigned to the Total Blepharospasm Group, patients with ≥21 onabotulinumtoxin-A injections to the Ona Long-Term Group. Read More

View Article and Full-Text PDF
February 2022

[Dry eye and qualitative tear alteration in essential blepharospasm].

Authors:
B Girard S Begnaud

J Fr Ophtalmol 2022 Mar 8;45(3):288-297. Epub 2022 Feb 8.

Service d'ophtalmologie, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; UPMC Sorbonne université, Paris, France; École de l'Inserm, fondation Bettencourt-Schueller, Paris, France.

Purpose: We aimed to analyze the tears of patients with Benin Essential Blepharospasm (BEB) to explore possible corneo-conjunctival mechanisms for photophobia, tear deficiency and ocular pain.

Methods: Using an observational cohort of 42 patients diagnosed with BEB, we performed Schirmer's testing, measurement of tear film pH, tear film protein electrophoresis and conjunctival impression cytology.

Results: Schirmer's testing showed dry eye (8. Read More

View Article and Full-Text PDF

Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study.

Graefes Arch Clin Exp Ophthalmol 2022 May 24;260(5):1707-1712. Epub 2022 Jan 24.

Goldschleger Eye Institute, Sheba Medical Center, Tel-Hashomer, Israel.

Objective: To examine the efficacy and safety of medical cannabis in benign essential blepharospasm (BEB).

Methods: This is a prospective, double-blind, placebo-controlled study. All consecutive adult BEB patients who had been treated with BTX-A injections without success between 3/2019 and 2/2020 were recruited. Read More

View Article and Full-Text PDF

Evaluation of ocular blood flow by Doppler ultrasound in patients with essential blepharospasm.

J Ultrasound 2021 Dec 2. Epub 2021 Dec 2.

Akdeniz University School of Medicine, Antalya, Turkey.

Purpose: Benign essential blepharospasm (EB) is a focal facial dyskinesia that occurs with the involuntary contraction of muscles around the eyes. In the literature, studies on blepharospasm focus on elucidating the pathophysiology of this condition in the brain. To the best of our knowledge, there is no research evaluating the orbital imaging findings of patients with EB. Read More

View Article and Full-Text PDF
December 2021

Oromandibular Dystonia: A Clinical Examination of 2,020 Cases.

Front Neurol 2021 16;12:700714. Epub 2021 Sep 16.

Department of Neurology, Emory University, Atlanta, GA, United States.

The goal of this study is to better characterize the phenotypic heterogeneity of oromandibular dystonia (OMD) for the purpose of facilitating early diagnosis. First, we provide a comprehensive summary of the literature encompassing 1,121 cases. Next, we describe the clinical features of 727 OMD subjects enrolled by the Dystonia Coalition (DC), an international multicenter cohort. Read More

View Article and Full-Text PDF
September 2021

Outcomes of a regional variant of botulinum toxin type A in the treatment of essential blepharospasm and hemifacial spasms: A retrospective study.

Indian J Ophthalmol 2021 Oct;69(10):2777-2781

Department of General Ophthalmology, Aravind Eye Hospital and PG Institute of Ophthalmology, Tirunelveli, Tamil Nadu, India.

Purpose: The aim of this study was to report the outcomes of a regional variant of botulinum toxin type A (BtA) in essential blepharospasm and hemifacial spasm.

Methods: The medical records of all patients with facial dystonias, who received at least one dose of BtA between May 2016 and April 2017 were retrospectively evaluated. The pre- and post-injection severity of symptoms, graded using the Jankovic rating system for essential blepharospasm and the Samsung Medical Center grading system for hemifacial spasm, the complications after each sitting, and the mean symptom-free interval were recorded. Read More

View Article and Full-Text PDF
October 2021

A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.

Neuroophthalmology 2021 19;45(5):293-300. Epub 2021 May 19.

Department of Ophthalmology, Tung Wah Eastern Hospital, Hong Kong, China.

This article reports the tolerance and long-term safety profiles of botulinum neurotoxin type A among Asian patients with benign essential blepharospasm (BEB) and hemifacial spasm (HFS). We performed a retrospective review of clinical documents and procedure records of consecutive BEB and HFS patients receiving onabotulinum toxin A (Botox) treatment in our clinic over the past 20 years. We reviewed the information of 105 patients diagnosed with BEB ( = 31) and HFS ( = 74). Read More

View Article and Full-Text PDF

Efficacy of Repetitive Transcranial Magnetic Stimulation Combined with Botulinum Toxin Type A for Benign Essential Blepharospasm Patients Accompanied by Anxiety and Depression.

Neuropsychiatr Dis Treat 2021 17;17:2707-2711. Epub 2021 Aug 17.

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.

Objective: To evaluate the improvement of motor, anxiety, and depression in patients with blepharospasm with the use of botulinum toxin type A (BTX-A) and repetitive transcranial magnetic stimulation (rTMS).

Methods: A total of 63 BEB patients accompanied by anxiety/depression were enrolled, among which 28 patients were treated with the injection of botulinum toxin type A (BTX-A) alone, while 35 patients were treated with BTX-A injection combined with rTMS. All patients were followed up for 6 months, and the overall efficacy was evaluated. Read More

View Article and Full-Text PDF

White Matter Hyperintensities Are Associated With Severity of Essential Tremor in the Elderly.

Front Neurol 2021 28;12:694286. Epub 2021 Jun 28.

Department of Neurology, University Hospital Schleswig-Holstein, Christian-Albrechts University, Kiel, Germany.

Essential tremor (ET) occurs with steeply increasing prevalence in the elderly, and apart from disease duration, age is independently associated with an increase of tremor amplitude and a decrease of frequency. White matter hyperintensities (WMHs) are a common finding in the elderly, and their role in the pathophysiology of ET is unknown. The aims of this study were to examine whether ET patients differ in their total or region-specific WMH volumes from healthy controls and to determine the impact of WMH on tremor characteristics. Read More

View Article and Full-Text PDF

Long-term stable efficacy of botulinum toxin A in facial movement disorders with no need for increasing dose.

Medicine (Baltimore) 2021 Jun;100(25):e26481

Department of Neurosurgery, Rambam Medical Center, Haifa, Israel.

Abstract: Botulinum toxin A is considered an effective treatment for involuntary facial movements. We examined whether treatment efficacy maintained or changed over time with two products, Botox and Dysport, in patients with hemifacial spasm, facial synkinesis and benign essential blepharospasm.We retrospectively investigated 87 consecutive patients (51 women, 36 men) who had undergone treatment for ≥6 years. Read More

View Article and Full-Text PDF

Outcome of Injection Botulinum Toxin in Blepharospasm.

Nepal J Ophthalmol 2021 Jan;13(25):40-49

Tilganga Institute of Ophthalmology, Nepal.

Introduction: Blepharospasm is a condition of involuntary spasm of the orbicularis oculi muscle which leads to intermittent or complete closure of the eyelids. Botulinum toxin is the currently recommended first line treatment for such blepharospasm. This study aims to find out the outcome of injection Botulinum toxin Type A in Blepharospasm. Read More

View Article and Full-Text PDF
January 2021

Complications of Preseptal Versus Pretarsal Botulinum Toxin Injection in Benign Essential Blepharospasm: A Randomized Controlled Trial.

Am J Ophthalmol 2021 12 7;232:9-16. Epub 2021 May 7.

Biostatistics Excellence Center, Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Purpose: The purpose of this study was to compare ocular complications and efficacy of preseptal (PST) versus those of pretarsal (PTS) botulinum toxin type A (BoNT-A) therapy in cases of benign essential blepharospasm (BEB).

Design: Randomized clinical trial.

Methods: Setting: university hospital. Read More

View Article and Full-Text PDF
December 2021

Disabling muscle of Riolan: A novel concept of orbicularis oculi myectomy for refractory benign essential blepharospasm.

Eur J Ophthalmol 2021 Nov 12;31(6):3411-3417. Epub 2021 Feb 12.

Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, Nagakute, Aichi, Japan.

Purpose: To examine the effectiveness of orbicularis oculi myectomy with disabling the muscle of Riolan in patients with benign essential blepharospasm refractory to botulinum toxin-A (BTX-A) injection.

Methods: This retrospective, observational study included 25 patients. After removal of the redundant skin and underlying orbicularis oculi muscle (OOM) with or without extended OOM removal to the area of the superior orbital rim, the tarsal plate and the gray line were vertically severed at 2 points to disable the muscle of Riolan. Read More

View Article and Full-Text PDF
November 2021

Quality of life in isolated dystonia: non-motor manifestations matter.

J Neurol Neurosurg Psychiatry 2021 Feb 9. Epub 2021 Feb 9.

Department of Neurology, University of Luebeck, Luebeck, Germany

Objective: To evaluate the relationship between health-related quality of life (HR-QoL) and both physical and psychiatric factors in a large, international, multicentre cohort of patients with isolated dystonia, the Dystonia Coalition.

Methods: Natural history data from 603 patients with isolated dystonia (median age 57 years (IQR: 48 to 64 years), 67.0% women) were prospectively acquired and analysed. Read More

View Article and Full-Text PDF
February 2021

Voxel-Wise Brain-Wide Functional Connectivity Abnormalities in Patients with Primary Blepharospasm at Rest.

Neural Plast 2021 6;2021:6611703. Epub 2021 Jan 6.

Department of Neurology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, China.

Background: Primary blepharospasm (BSP) is one of the most common focal dystonia and its pathophysiological mechanism remains unclear. An unbiased method was used in patients with BSP at rest to observe voxel-wise brain-wide functional connectivity (FC) changes.

Method: A total of 48 subjects, including 24 untreated patients with BSP and 24 healthy controls, were recruited to undergo functional magnetic resonance imaging (fMRI). Read More

View Article and Full-Text PDF
October 2021

Antibody Development in Patients Treated Long-Term With OnabotulinumtoxinA for Benign Essential Blepharospasm and Hemifacial Spasm.

J Neuroophthalmol 2021 Dec;41(4):e684-e687

Division of Ophthalmology (CNC, RB), Section Oculofacial Plastic and Reconstructive Surgery, Ohio University/Ohio Health Doctor's Hospital, Columbus, Ohio; and Department of Ophthalmology (CNC, JAB), Oral and Maxillofacial Surgery, Grant Medical Center, Columbus, Ohio.

Background: Report the development of onabotulinumtoxinA neutralizing antibodies in patients treated consecutively for 20 years or longer for benign essential blepharospasm (BEB), hemifacial spasm (HFS), and Meige Syndrome.

Methods: Prospective, randomized, cross-sectional study of 12 randomly selected patients from a single clinical practice that have been treated consecutively for 20 or more years with onabotulinumtoxinA for BEB, HFS, or Meige Syndrome. Serum samples were collected from each subject and analyzed for neutralizing antibody formation using the Mouse Protection Assay. Read More

View Article and Full-Text PDF
December 2021

Impact of Upper Eyelid Surgery on Symptom Severity and Frequency in Benign Essential Blepharospasm.

J Mov Disord 2021 Jan 12;14(1):53-59. Epub 2021 Jan 12.

Blepharospasm Clinic, Moorfields Eye Hospital NHS Foundation Trust, London, UK.

Objective: To assess the impact of periocular surgery, other than orbicularis stripping, on the severity and frequency of blepharospasm symptoms.

Methods: Consecutive patients with benign essential blepharospasm (BEB) who underwent eyelid/eyebrow surgery with the aim of improving symptoms were retrospectively reviewed over a 5-year period. Patients who had completed the Jankovic Rating Scale (JRS) and Blepharospasm Disability Index (BDI) pre- and at least 3 months postoperatively were included. Read More

View Article and Full-Text PDF
January 2021

Disease modifying treatment trials in Parkinson's disease: how to balance expectations and interests of patients, physicians and industry partners?

Neurol Res Pract 2020 2;2:31. Epub 2020 Nov 2.

Department of Neurology, Christian-Albrecht University of Kiel, Arnold-Heller-Straße 3, 24105 Kiel, Germany.

Background: The advent of therapeutic strategies designed to modify the disease course in Parkinson's disease has raised great expectations in the currently conducted clinical trials. However, we see ethical challenges in the cooperation of industry and clinical partners, specifically evident in the way recruitment is performed.We here discuss the different positions and challenges of all involved to set the stage for a study and recruitment culture taking into account the expectations of all: (i) patients and their caregivers, ready to take the considerable burden of clinical trials in hope for the development of disease-modifying treatments; (ii) physicians and study nurses, obligated to the patients' well-being and benefit who accompany and supervise patients closely as basis for the performance of elaborate clinical trials (iii) industrial partners, investing years of efforts and finances to develop new treatments. Read More

View Article and Full-Text PDF
November 2020

Eye pain in the white and quiet eye.

Curr Opin Ophthalmol 2020 Nov;31(6):483-488

Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, MN.

Purpose Of Review: Eye pain is one of the most common presenting symptoms in ophthalmology. It can range from bothersome to debilitating for patients, and it can be vexing for clinicians, especially in the white and quiet eye. The purpose of this review is to provide updates of recent literature regarding eye pain and to communicate our current understanding regarding the evaluation and management of conditions that cause eye pain with a relatively normal examination. Read More

View Article and Full-Text PDF
November 2020

[Blepharospasm, dry eye and extractable nuclear antigen antibodies (French translation of the article)].

J Fr Ophtalmol 2020 Oct 4;43(8):691-696. Epub 2020 Sep 4.

Département de santé publique, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; Inserm, Institut Pierre-Louis de Santé Publique, France; UPMC Sorbonne université, Paris, France.

Purpose: The goal of this study is to determine a link between benign essential blepharospasm and Sjogren's syndrome by analyzing the presence of extractable nuclear antigens in this population.

Methods: Seventy-two patients with benign essential blepharospasm (BEB) were included in this study. We eliminated patients with hemifacial spasm or blepharospasm secondary to corneal pathology. Read More

View Article and Full-Text PDF
October 2020

Blepharospasm: Is it really a "Benign" or an "Essential" Condition?

Authors:
Sameera Irfan

Nepal J Ophthalmol 2020 Jan;12(23):4-6

FRCS (UK); Lahore, Pakistan.

View Article and Full-Text PDF
January 2020

Botulinum toxin for benign essential blepharospasm: A systematic review and an algorithmic approach.

Rev Neurol (Paris) 2021 Jan-Feb;177(1-2):107-114. Epub 2020 Jul 9.

Department of Plastic and Reconstructive Surgery, Faculty of Medicine, Saint-Joseph University, Hôtel-Dieu de France Hospital, Beirut, Lebanon.

Background: Currently, there is no standardised approach for benign essential blepharospasm treatment with botulinum toxin, and controversies still exist regarding this subject.

Objective: The objective of this systematic review is to summarise and compare all the published data regarding benign essential blepharospasm treatment with botulinum toxin.

Methods: On October 3, 2018, an online search of the Medline database was conducted. Read More

View Article and Full-Text PDF

The good toxin: 10 years of experience with botulinum toxin A in the treatment of benign essential blepharospasm.

Eur J Ophthalmol 2021 May 26;31(3):1345-1350. Epub 2020 May 26.

Department of Ophthalmology, Tung Wah Eastern Hospital, Causeway Bay, Hong Kong.

Purpose: To describe the efficacy and safety of botulinum toxin A (Botox) in patients with benign essential blepharospasm.

Methods: Retrospective review of operation, injection, and medical records.

Results: Information of 29 patients (nine males) was reviewed, and the average age of benign essential blepharospasm onset was 59. Read More

View Article and Full-Text PDF

Blepharospasm, dry eye and extractable nuclear antigen antibodies.

J Fr Ophtalmol 2020 Sep 10;43(7):e211-e215. Epub 2020 Jun 10.

Département de santé publique, hôpital Tenon, Assistance publique-Hôpitaux de Paris, 4, rue de-la-Chine, 75970 Paris cedex 20, France; INSERM, institut Pierre-Louis de santé publique, UPMC Sorbonne université, Paris, France.

Purpose: To study whether there is an association between benign essential blepharospasm and Sjögren's syndrome by analyzing the presence of antibodies to extractable nuclear antigens in this population.

Methods: Seventy-two patients with benign essential blepharospasm (BEB) were included in this study. We excluded patients with hemifacial spasm or blepharospasm secondary to known corneal pathology. Read More

View Article and Full-Text PDF
September 2020

Medical and Surgical Treatments for Dystonia.

Authors:
H A Jinnah

Neurol Clin 2020 05 2;38(2):325-348. Epub 2020 Mar 2.

Department of Neurology, Emory University School of Medicine, Suite 6305 Woodruff Memorial Building, Atlanta, GA 30322, USA; Department of Human Genetics, Emory University School of Medicine, Suite 6305 Woodruff Memorial Building, Atlanta, GA 30322, USA. Electronic address:

The dystonias are a large and heterogenous group of disorders characterized by excessive muscle contractions leading to abnormal postures and/or repetitive movements. Their clinical manifestations vary widely, and there are many potential causes. Despite the heterogeneity, helpful treatments are available for the vast majority of patients. Read More

View Article and Full-Text PDF

Serum calcium, magnesium, phosphorus, and vitamin D in benign essential blepharospasm.

Graefes Arch Clin Exp Ophthalmol 2020 Jun 31;258(6):1293-1297. Epub 2020 Mar 31.

University of Health Sciences, Beyoglu Eye Training and Research Hospital, Bereketzade Mahallesi, Bereketzade Camii Sokak, NO:2, Pbx: 34420 Beyoğlu, Istanbul, Turkey.

Purpose: This study aims to compare serum calcium, magnesium, phosphorus, and 25-hydroxy (OH)-vitamin D levels in patients with benign essential blepharospasm (BEB) and healthy subjects and to determine their association with disease severity and frequency.

Methods: This is a prospective study conducted in a tertiary care hospital. Fifty patients (female, 39; male, 11) with BEB and 22 healthy subjects (female, 15; male, 7) included in the study. Read More

View Article and Full-Text PDF

Which factors impact on quality of life for adults with blepharospasm and hemifacial spasm?

Orbit 2021 Apr 1;40(2):110-119. Epub 2020 Mar 1.

Moorfields Eye Hospital NHS Foundation Trust , London, UK.

: Benign essential blepharospasm (BEB) and hemifacial spasm (HFS) are debilitating conditions causing spasms to the eyes and/or face and can significantly impact on quality of life (QoL). Initial research has highlighted potential factors impacting on QoL in BEB, but there remains a wealth of demographic, clinical, and psychosocial factors that may contribute to QoL but have not received attention. : Cross-sectional baseline data were collected before a single-masked randomised controlled trial from 130 adults with BEB and HFS recruited from botulinum toxin clinics at Moorfields Eye Hospital, London. Read More

View Article and Full-Text PDF